LogicBio Therapeutics, Inc. (LOGC)

Nov 16, 2022 - LOGC was delisted (reason: acquired by Alexion, AstraZeneca Rare Disease)
2.07
0.00 (0.00%)
Last trade price
Market Cap 68.23M
Revenue (ttm) 10.16M
Net Income (ttm) -30.95M
Shares Out 32.96M
EPS (ttm) -1.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 152,923
Open 2.06
Previous Close 2.07
Day's Range 2.06 - 2.07
52-Week Range 0.26 - 3.53
Beta 4.62
Analysts Buy
Price Target 2.30 (+11.1%)
Earnings Date Nov 21, 2022

About LOGC

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials fo... [Read more]

Industry Biotechnology
IPO Date Oct 19, 2018
CEO Frederic Chereau
Employees 62
Stock Exchange NASDAQ
Ticker Symbol LOGC
Full Company Profile

Financial Performance

In 2021, LOGC's revenue was $5.41 million, an increase of 56.63% compared to the previous year's $3.45 million. Losses were -$40.03 million, 22.7% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for LOGC stock is "Buy." The 12-month stock price forecast is 2.3, which is an increase of 11.11% from the latest price.

Price Target
$2.3
(11.11% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics

WILMINGTON, Del.--( BUSINESS WIRE )--Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine co...

2 weeks ago - Business Wire

LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

- Pre-clinical results published in PLOS ONE demonstrating a single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality whe...

3 weeks ago - PRNewsWire

LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigate...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C.

1 month ago - Business Wire

INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGC

NEW YORK , Oct. 3, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated...

2 months ago - PRNewsWire

SHAREHOLDER ALERT: Weiss Law Investigates LogicBio Therapeutics, Inc.

NEW YORK , Oct. 3, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of LogicBio Therapeutics, Inc. ("LogicBio" or...

2 months ago - PRNewsWire

Shareholder Alert: Ademi LLP investigates whether LogicBio® Therapeutics, Inc. has obtained a Fair Price in its trans...

MILWAUKEE , Oct. 3, 2022 /PRNewswire/ -- Ademi LLP is investigating LogicBio (NASDAQ: LOGC) for possible breaches of fiduciary duty and other violations of law in its transaction with AstraZeneca.  Clic...

2 months ago - PRNewsWire

Why Is LogicBio (LOGC) Stock Up 600% Today?

Source: Roland Magnusson / Shutterstock.com LogicBio (NASDAQ: LOGC ) stock is seeing massive gains on Monday following news that AstraZeneca (NASDAQ: AZN ) subsidiary Alexion is acquiring the clinical-s...

2 months ago - InvestorPlace

LogicBio's stock skyrockets after buyout bid for a 667% premium

Shares of LogicBio Therapeutics Inc. LOGC, +641.32% skyrocketed more than seven-fold (up 643%) in morning trading, to bounce off the previous session's record low, after the genetic medicine company ann...

Other symbols: AZN
2 months ago - Market Watch

LOGC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LogicBio Therapeutics, Inc. Is Fair to Shareh...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) to AstraZeneca Rare Disease for $2.07 per share ...

2 months ago - Business Wire

AstraZeneca pays 660% premium for gene therapy firm LogicBio

Shares of LogicBio Therapeutics skyrocketed on Monday after Britain's AstraZeneca's said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million.

Other symbols: AZN
2 months ago - Reuters

Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine

WILMINGTON, Del.--(BUSINESS WIRE)--Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics, Inc. (NASDAQ: L...

2 months ago - Business Wire

5 Big Winners as Dollar Strengthens on Fed Rate Hike

A stronger dollar is a boon for Consolidated Water (CWCO), Ashford Hospitality Trust (AHT), BankFinancial (BFIN), LogicBio Therapeutics (LOGC) and ProPhase Labs (PRPH) that have high domestic exposure i...

Other symbols: AHTBFINCWCOPRPH
2 months ago - Zacks Investment Research

5 Winning Stocks Backed by the Overlooked Trick of Rising P/E

Want to try an out-of-the-box approach? Tap Eastside Distilling (EAST), LogicBio Therapeutics (LOGC), Seabridge Gold (SA), Suzano (SUZ) and J Douglas Emmett (DEI).

Other symbols: DEIEASTSASUZ
2 months ago - Zacks Investment Research

LogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE

Single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when challenged with a high protein diet. LEXINGTON, Mass.

2 months ago - PRNewsWire

LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

- Interim data from SUNRISE trial in four pediatric patients showed detectable levels of ALB-2A biomarker demonstrating site-specific gene insertion and protein expression - Two of four patients demonst...

3 months ago - PRNewsWire

LogicBio Therapeutics (LOGC) Moves to Buy: Rationale Behind the Upgrade

LogicBio Therapeutics (LOGC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

4 months ago - Zacks Investment Research

LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference

LEXINGTON, Mass., May 17, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic...

6 months ago - PRNewsWire

LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates

–FDA lifted  clinical hold on SUNRISE trial in pediatric patients with methylmalonic acidemia –Interim clinical data from Phase 1/2 trial expected to be presented by end of second quarter 2022 –LogicBio...

6 months ago - PRNewsWire

LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in...

- GeneRide ® LB-401 preclinical data in HT1 demonstrated substantial and durable reduction of disease-related biomarkers -Proprietary AAV transfection process, harnessing mAAVRx™ system, showed 15- to 3...

6 months ago - PRNewsWire

Why LogicBio Therapeutics Shares Are Popping Off Today

LogicBio Therapeutics Inc (NASDAQ: LOGC) shares are trading higher by 63.48% at $0.81 after the company announced the FDA lifted the clinical hold on its LB-001 Investigational New Drug Application, all...

6 months ago - Benzinga

LogicBio Therapeutics Shares Skyrocket As FDA Lifts Clinical Hold On Its Pediatric Trial

The FDA has lifted the clinical hold on LogicBio Therapeutics Inc's (NASDAQ: LOGC) LB-001 Investigational New Drug Application (IND) to resume patient enrollment in Phase 1/2 SUNRISE trial in pediatric ...

6 months ago - Benzinga

LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Aci...

–Company initiates activities to resume dosing –Interim clinical data from Phase 1/2 trial expected to be presented by end of second quarter 2022 LEXINGTON, Mass. , May 9, 2022 /PRNewswire/ -- LogicBio®...

6 months ago - PRNewsWire

LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference

LEXINGTON, Mass. , March 23, 2022 /PRNewswire/ -- LogicBio ®  Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Fr...

8 months ago - PRNewsWire

LogicBio Therapeutics to Present at Barclays Global Healthcare Conference

LEXINGTON, Mass., March 8, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Freder...

8 months ago - PRNewsWire

LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates

LEXINGTON, Mass., March 4, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended December 31, 2...

9 months ago - PRNewsWire